SUBSCRIBE
SUBSCRIBE

Alector, LLC

NEWS
Business
AbbVie Plows $205M Upfront Into Alector’s Alzheimer’s Program
AbbVie announced a strategic collaboration with Alector to develop and commercialize drugs for ALZ’s disease and other neurodegenerative disorders.
October 24, 2017
 · 
3 min read
 · 
Mark Terry
Load More
AWARDS
  • NextGen Class of 2015
JOBS
IN THE PRESS
Drug Development
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)
September 9, 2021
 · 
6 min read
Genetown
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
June 2, 2021
 · 
6 min read
Business
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
March 25, 2020
 · 
5 min read
Business
Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.
March 20, 2020
 · 
1 min read
Drug Development
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients
January 31, 2020
 · 
5 min read
Biotech Bay
Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day
December 16, 2019
 · 
7 min read
Business
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee
December 16, 2019
 · 
5 min read
Business
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer
December 12, 2019
 · 
3 min read
Biotech Bay
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
July 18, 2019
 · 
4 min read
Business
Winterlight is developing speech-based digital biomarkers to monitor disease progression in patients with FTD in collaboration with Alector
July 9, 2019
 · 
2 min read
Load More